NCT06487546NARecruiting

Repletion of Ergothioneine in Patients With Kidney Failure

Stanford University

Start Date

4/1/2025

Completion Date

12/1/2030

Summary

Dialysis removes potentially harmful chemicals from the blood but can also remove potentially valuable chemicals. One potentially valuable chemical called ergothioneine, which comes from the diet, is low in the blood of people receiving dialysis. For this research study, the investigators hope to learn how well a daily ergothioneine supplement will replenish the levels in the blood of people with kidney failure.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * kidney failure receiving hemodialysis or peritoneal dialysis Exclusion Criteria: * blood transfusion within 90 days * taking supplements which contain ergothioneine

Interventions

DIETARY_SUPPLEMENT

Ergothioneine

OTHER

Placebo

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Esrd

Locations

Veterans Affairs Palo Alto

Palo Alto, California 94304

United States

Run studies, or work at a research site?

Corterve helps sites and sponsors reach patients who are looking for trials. It does not determine eligibility and does not promise an enrolment outcome.

For sponsors, CROs and sites

What Corterve sells to organisations, and the anti-kickback constraints it works within.

Services and published prices

Lay summaries for EU CTR Annex V, pre-screen filtration, recruitment-creative regulatory operations, feasibility reporting.

For research sites

One published licence rate, the same for every site, and the fees a site is never charged.